cancer
Hub71’s Vivan Therapeutics wins approval for cancer study
Vivan Therapeutics, part of Hub71 and a precision oncology company developing AI-enabled tools to match cancer patients to more effective therapies, today announced that it has received all regulatory...
BioSapien raises $5.5mln in pre-series a funding led by Global Ventures
BioSapien, the patented drug delivery platform treating cancer ‘locally’, announces its $5.5 million (20.2M AED) pre-Series A fundraise. The funding was led by Global Ventures – MENA’s leading VC firm...